This Directive represents an important step towards achievement of the objective of the free movement of medicinal products. Further measures may abolish any remaining barriers to the free movement of proprietary medicinal products will be necessary in the light of experience gained, particularly in the abovementioned Committee for Proprietary Medicinal Products.
Recital 14, Directive (EU) 2001/83
The 10 that are cited most themselves, of 11.
Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecision
That is particularly true as regards the procedure for mutual recognition established by Article 28 of Directive 2001/83. In accordance with the objective of abolishing all barriers to the free movement of medicinal products in the …
16 Oct 2008 · 62006CJ0452
Judgment of the Court (Third Chamber) of 11 June 2020. ratiopharm GmbH v Novartis Consumer Health GmbH.Decision
Recitals 2 to 4, 14, 45 to 47, 50 and 51 of Directive 2001/83 are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. However, this …
11 Jun 2020 · 62018CJ0786
Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decision
Recital 14 of Directive 2001/83 states that the directive represents an important step towards achievement of the objective of the free movement of medicinal products.
14 Mar 2018 · 62016CJ0557
Opinion of Advocate General Bobek delivered on 7 December 2017. Proceedings brought by Astellas Pharma GmbH.Decision
In sum, the genuine operation of the decentralised procedure, despite it forming part of a regime heralded as an ‘important step towards achievement of the objective of the free movement of medicinal products’, [Recital 14 of the …
7 Dec 2017 · 62016CC0557
Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision
It is also true that, with regard to the decentralised procedure, referred to in Article 28(3) of Directive 2001/83, the Court of Justice has held that, once the general agreement of the Member States in which the application for marketing …
5 May 2021 · 62018TJ0611
Judgment of the Court (First Chamber) of 20 September 2007. Staat der Nederlanden v Antroposana, Patiëntenvereniging voor Antroposofische GeDecision
That conclusion is not called into question by the argument put forward by Antroposana and Others and the German Government to the effect that the harmonisation process in the field of medicinal products for human use is being carried out …
20 Sep 2007 · 62006CJ0084
Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision
It is apparent from a combined reading of Article 1(28a) and Article 26 of Directive 2001/83, as well as Article 12 of Regulation No 726/2004, read in the light of recital 14 of that regulation, that an MA is to be refused where, after …
19 Dec 2019 · 62018TJ0211
Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision
Recitals 2 to 5, 14, 40 and 41 of Directive 2001/83 state: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. However, this objective must be attained by …
17 Nov 2022 · 62020CJ0224
Opinion of Advocate General Sharpston delivered on 30 May 2013. Laboratoires Lyocentre v Lääkealan turvallisuus- ja kehittämiskeskus and SosDecision
Recital 2 in the preamble to the Medicinal Products Directive states that ‘[t]he essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health’. Recital 14 describes …
30 May 2013 · 62012CC0109
Opinion of Advocate General Pitruzzella delivered on 30 January 2020. ratiopharm GmbH v Novartis Consumer Health GmbH.Decision
The Court has already held that ‘advertising of medicinal products is liable to harm public health, the safeguarding of which is the essential aim of Directive 2001/83’. [Judgment of 5 May 2011, Novo Nordisk (C‑249/09, EU:C:2011:272, …
30 Jan 2020 · 62018CC0786